{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T14:50:45Z","timestamp":1773586245240,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7662,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1999,1]]},"DOI":"10.1023\/a:1008354600497","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"33-38","source":"Crossref","is-referenced-by-count":117,"title":["Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma"],"prefix":"10.1016","volume":"10","author":[{"given":"W.","family":"Kreis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Budman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fetten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Barile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008354600497_bb0005","first-page":"356","article-title":"Docetaxel (Taxotere): A review of preclinical and clinical experience","volume":"6","author":"van Oosterom","year":"1995","journal-title":"Part II: Clinical experience. Anti-Cancer Drugs"},{"key":"10.1023\/A:1008354600497_bb0010","first-page":"489","article-title":"Preclinical in vivo activity of docetaxel containing combinations","volume":"14","author":"Bissery","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","article-title":"Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol","volume":"83","author":"Ringel","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008354600497_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1464-410X.1997.06310.x","article-title":"Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines","volume":"79","author":"Kreis","year":"1997","journal-title":"Br J Urol"},{"key":"10.1023\/A:1008354600497_bb0025","first-page":"4433","article-title":"Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines","volume":"52","author":"Speicher","year":"1992","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008354600497_bb0030","first-page":"4573","article-title":"Estramustine depolymerizes microtubules by binding to tubulin","volume":"53","author":"Dahllof","year":"1993","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008354600497_bb0035","first-page":"268","article-title":"The effects of estramustine on metaphase and anaphase in DU 145 prostate carcinoma cells","volume":"54","author":"Sheridan","year":"1991","journal-title":"Eur J Cell Biol"},{"key":"10.1023\/A:1008354600497_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bjc.1991.290","article-title":"Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype","volume":"64","author":"Speicher","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008354600497_bb0045","first-page":"2584","article-title":"Increase of beta (III) and beta (IVa)-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance","volume":"56","author":"Ranganathan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008354600497_bb0050","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0006-2952(97)00657-6","article-title":"Androgen antagonistic effect of estramustine phosphate metabolites on wild-type and mutated androgen receptor","volume":"55","author":"Wang","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1023\/A:1008354600497_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1023\/A:1008354600497_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","article-title":"Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","volume":"11","author":"Kelly","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0065","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.1998.16.10.3398","article-title":"Apples and Oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials","volume":"16","author":"Dawson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0070","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1200\/JCO.1992.10.11.1754","article-title":"Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer","volume":"10","author":"Hudes","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0075","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0022-5347(17)37432-3","article-title":"The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer","volume":"147","author":"Miller","year":"1992","journal-title":"J Urol"},{"key":"10.1023\/A:1008354600497_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0090-4295(96)00017-9","article-title":"Acid phosphatase: Defining a role in androgen-independent prostate cancer","volume":"47","author":"Steineck","year":"1996","journal-title":"Urology"},{"key":"10.1023\/A:1008354600497_bb0085","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T","article-title":"The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer","volume":"76","author":"Small","year":"1995","journal-title":"Cancer"},{"key":"10.1023\/A:1008354600497_bb0090","series-title":"Concepts, Mechanisms, and New Targets for Chemotherapy","first-page":"163","article-title":"Estramustine revisited","author":"Kreis","year":"1995"},{"key":"10.1023\/A:1008354600497_bb0095","first-page":"1614A","article-title":"Management of fluid retention syndrome in patients with Taxotere (docetaxel): Effect of premedication","volume":"13","author":"Oulid-Aissa","year":"1994","journal-title":"Proc Ann Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0100","first-page":"124A","article-title":"Efficacy of a five-day corticosteroid premedication in ameliorating Taxotere induced fluid retention","volume":"15","author":"Ravdin","year":"1996","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Docetaxel","volume":"13","author":"Cortes","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0110","first-page":"28","article-title":"Metastatic prostate cancer: Assessment of response to systemic therapy","volume":"15","author":"Dreicer","year":"1997","journal-title":"Semin Urol Oncol"},{"key":"10.1023\/A:1008354600497_bb0115","first-page":"1202a","article-title":"Phase I\u2013II study of the combination of estramustine phosphate (Emcyt) plus docetaxel (Taxotere) in patients with hormone refractory prostate cancer (HRPC)","volume":"16","author":"Kreis","year":"1997","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0120","first-page":"1103a","article-title":"Phase I trial of docetaxel (D) and estramustine (E) in androgen insensitive prostate cancer (AID)","volume":"16","author":"Petrylak","year":"1997","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00000421-199612000-00010","article-title":"Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer","volume":"19","author":"Attivissimo","year":"1996","journal-title":"Am J Clin Oncol"},{"issue":"6 Suppl 13","key":"10.1023\/A:1008354600497_bb0130","first-page":"17","article-title":"Docetaxel (Taxotere): An overview of first line monotherapy","volume":"22","author":"Trudeau","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008354600497_bb0135","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"issue":"Suppl 13","key":"10.1023\/A:1008354600497_bb0140","first-page":"3","article-title":"Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination","volume":"22","author":"Bissery","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008354600497_bb0145","first-page":"96","volume":"76","author":"Storlie","year":"1995","journal-title":"Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone refractory metastatic prostate carcinoma Cancer"},{"key":"10.1023\/A:1008354600497_bb0150","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.1995.13.12.2944","article-title":"Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy","volume":"13","author":"Sridhara","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008354600497_bb0155","first-page":"1143A","article-title":"A 75% decline in prostate-specific antigen (PSA) predicts survival in hormone refractory prostate cancer","volume":"34","author":"Thibault","year":"1993","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419570375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419570375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/10\/1\/33\/19477103\/10-1-33.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T23:26:38Z","timestamp":1582241198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419570375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["S0923753419570375"],"URL":"https:\/\/doi.org\/10.1023\/a:1008354600497","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}